|Manufacturer:||Aurobindo Pharma USA, Inc.|
Didanosine delayed-release capsules are not a cure for HIV-1 infection, and patients may continue to develop HIV-associated illnesses, including opportunistic infection.
Therefore, patients should remain under the care of a physician when using didanosine delayed-release capsules.
Patients should be advised that didanosine delayed-release capsules therapy has not been shown to reduce the risk of transmission of HIV to others through sexual contact or blood contamination.
Patients should be informed that the long-term effects of didanosine delayed-release capsulesare unknown at this time.
Didanosine delayed-release capsules, known as ddI, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (HIV)-1 infection [see Clinical Studies (14)].
-- any state of infection accompanied by evidence of HIV in the body (positive test for HIV genome, cDNA, proteins, antigens, or antibodies); may be medically asymptomatic or symptomatic; use AIDS when appropriate.
The following US Branded drugs contain Didanosine
-- BRISTOL MYERS SQUIBB CO
-- BRISTOL MYERS SQUIBB CO PHARMACEUTICAL RESEARCH INSTITUTE
This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor.
It should not to be used for self-diagnosis or treatment.